Ladarixin Sodium

N/A

Report date: 2024/11/08 20:00:30
NME

Base Information

Drug NameLadarixin Sodium
Drug Alias Name拉达利星Ladarixinum拉达立辛LadarixinaLadarixine +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-X-C motif chemokine receptor 2 antagonistsC-X-C motif chemokine receptor 1 antagonists
TargetsC-X-C motif chemokine receptor 1C-X-C motif chemokine receptor 2
Therapy Area/IndicationsDiabetes Mellitus, Type 1Pemphigoid, Bullous
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSerbia +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDompe Farmaceutici Spa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDompé farmaceutici SPA
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1Pemphigoid, Bullous

Other Information

ATC CodeN/A
Related LinksN/A